A couple of weeks ago, I read a post by Cris Frangold.  Cris pronounces a love for investing and writing about it.  I would consider him or her a financial blogger, with a  focus on medical services and the health sector.
   The piece that I read in Seeking Alpha regarded the value of Merck and purchasing its stock.  One reason offered to invest in the company was its drug Januvia.  Januvia is meant to treat the symptoms of type 2 diabetes.  Cris noted that 2012 Q2 sales of the drug were over 1billion dollars. Then he or she said:
Januvia has a potential to be a real moneymaker because the American Diabetes Association estimates that 25.8 Americans, or 8.3% of the population have Type 1 and Type 2 diabetes - the majority are Type 2.
   Type 2 diabetes in adults and children is related to diet - diet as it produces obesity.  It appears that excess body fat leads to metabolic dysfunction or disregulation so that blood sugar, blood pressure, and cholesterol irregularities follow.   Our diabetes rates have doubled in the past 30 years in tandem with our increase in obesity.  The 30 year trend of rising weights has been attributed to an increase in availability and consumption of high calorie, nutrient poor foods and beverages.
   Sure we can make billions on treatment and millions investing in those treatment options, but isn't there a better response?  I suggest that there is.  Investing in a diabetes drug means counting on a disease to continue, needing it to continue in order to enhance a portfolio or fund a retirement account.  That seems to be a good example of maleficence.    
   What of the better good?  I say the noble thing to do is invest in the food environment so that meals and drinks contain reasonable amounts of sat fat, sugar and calories.  And yes - sometimes that takes a mandate.

 American Diabetic Association
National Diabetes Information Clearinghouse.  Program of the National Institutes of Health